Press Releases
2009
June
06/08/2009XOMA Presents Data At ADA Demonstrating Improvement in Diabetes and Inflammatory Measures in Animal Model With XOMA 052
06/06/2009
XOMA 052 Clinical Results Support Novel Anti-Inflammatory Approach to Type 2 Diabetes Treatment
06/05/2009
XOMA Announces $12.0 Million Financing
06/04/2009
XOMA to Present At Annual Needham Life Sciences Conference On June 10, 2009
May
05/26/2009XOMA Announces Clinical and Preclinical Presentations At American Diabetes Association 69th Scientific Sessions
05/15/2009
XOMA Announces $10 Million Financing
05/14/2009
XOMA Royalties On CIMZIA(r) Expected to Increase Due to FDA Approval for Moderate to Severe Rheumatoid Arthritis in Adults
05/12/2009
XOMA Issued New U.S. Patent Covering Its XOMA 052 Lead Product Candidate
05/07/2009
XOMA Reports 2009 First Quarter Financial Results
05/05/2009
XOMA to Present At Canaccord Adams Diabetes & Obesity Conference on May 12, 2009
05/01/2009
XOMA to Announce First Quarter 2009 Financial Results and Host Conference Call On May 7
April
04/30/2009Enrollment Completed in Phase 1 Program for XOMA 052 in Type 2 Diabetes
March
03/16/2009XOMA to Present At Cowen Health Care Conference On March 18, 2009
03/11/2009
XOMA Reports 2008 Financial Results
03/04/2009
XOMA Initiates Phase 2a Clinical Trial With XOMA 052 in Patients With Rheumatoid Arthritis
03/04/2009
XOMA to Announce Fourth Quarter 2008 Financial Results and Host Conference Call On March 11
February
02/10/2009XOMA and Takeda Expand Collaboration
02/02/2009
XOMA to Present at the Biotechnology Industry Organization BIO CEO & Investor Conference on February 9, 2009
January
01/22/2009XOMA Receives Milestone Payment From Pfizer Under Antibody Technology License
01/20/2009
XOMA Updates Guidance for 2008
01/15/2009
XOMA Announces Workforce Reduction
01/05/2009
XOMA Appoints Fred Kurland as Chief Financial Officer
2008
December
12/11/2008XOMA Appoints John Varian to Board of Directors
12/10/2008
XOMA Provides Clinical Plan Update On Diabetes Drug Candidate
12/04/2008
XOMA Speaks On Inflammation and Rheumatology Panel At RBC Capital Markets Healthcare Conference
November
11/10/2008XOMA Reports Third Quarter 2008 Financial Results
11/10/2008
XOMA Restructures Drug Development Collaboration Including Oncology Drug Candidate HCD122
11/04/2008
XOMA to Announce Third Quarter 2008 Financial Results and Host Conference Call on November 10
11/04/2008
XOMA to Present at the Rodman and Renshaw Annual Global Investment Conference on November 11
October
10/28/2008XOMA Appoints Steve Doberstein to Vice President of Research
10/25/2008
XOMA Presents Data On XOMA 052, An Anti-IL-1 Beta Antibody, in Rheumatoid Arthritis and Acute Gout Animal Models
10/23/2008
XOMA to Present At the BIO Investor Forum On October 30
10/22/2008
XOMA Enters Into $60 Million Committed Equity Financing Facility
September
09/22/2008XOMA to Webcast Analyst and Investor Event 'Interleukin-1 Blockers: Unlocking Their Potential in Diabetes and Beyond' On September 25
09/16/2008
XOMA to Present At the UBS Global Life Sciences Conference On September 22
09/15/2008
New Programs Added in Antibody Collaboration Between XOMA and Takeda
09/10/2008
Texas A&M University System and XOMA Sign Memorandum of Understanding
09/09/2008
XOMA Awarded $65 Million Biodefense Contract by NIAID to Advance Drug Candidates Against Botulism Toxins Into Clinical Trials
09/08/2008
XOMA 052 Clinical Results Support New Type 2 Diabetes Therapeutic Approach of Targeting Inflammatory Damage to Insulin-Producing Cells
August
08/07/2008XOMA Reports Second Quarter 2008 Financial Results
08/04/2008
XOMA to Announce Second Quarter 2008 Financial Results and Host Conference Call On Thursday, August 7
July
07/28/2008XOMA Announces Departure of CFO
07/24/2008
XOMA Begins Phase 2a Clinical Trial to Evaluate XOMA 629 Topical Gel as a Treatment for the Common Skin Disease, Impetigo
07/15/2008
XOMA 052 Phase 1 Data to be Presented At European Association for the Study of Diabetes Annual Meeting
June
06/19/2008XOMA to Present At the Jefferies Healthcare Conference On June 26
06/07/2008
XOMA 052 Demonstrates Anti-Inflammatory Effect in Arthritis Animal Studies; Data Presented At FOCIS
06/07/2008
XOMA 052 Demonstrates Anti-Inflammatory Effects in Diabetes Animal Studies; Data Presented At ADA
06/05/2008
XOMA to Present At the Needham Biotechnology and Medical Technology Conference On June 11
